102 related articles for article (PubMed ID: 8358720)
1. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers.
LeMaistre CF; Craig FE; Meneghetti C; McMullin B; Parker K; Reuben J; Boldt DH; Rosenblum M; Woodworth T
Cancer Res; 1993 Sep; 53(17):3930-4. PubMed ID: 8358720
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.
Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE
Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331
[TBL] [Abstract][Full Text] [Related]
4. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.
Sewell KL; Parker KC; Woodworth TG; Reuben J; Swartz W; Trentham DE
Arthritis Rheum; 1993 Sep; 36(9):1223-33. PubMed ID: 8216416
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
6. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma.
Hesketh P; Caguioa P; Koh H; Dewey H; Facada A; McCaffrey R; Parker K; Nylen P; Woodworth T
J Clin Oncol; 1993 Sep; 11(9):1682-90. PubMed ID: 8355035
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
Frankel AE; Surendranathan A; Black JH; White A; Ganjoo K; Cripe LD
Cancer; 2006 May; 106(10):2158-64. PubMed ID: 16586495
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas.
Kuzel TM; Rosen ST; Gordon LI; Winter J; Samuelson E; Kaul K; Roenigk HH; Nylen P; Woodworth T
Leuk Lymphoma; 1993 Nov; 11(5-6):369-77. PubMed ID: 8124209
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
Platanias LC; Ratain MJ; O'Brien S; Larson RA; Vardiman JW; Shaw JP; Williams SF; Baron JM; Parker K; Woodworth TG
Leuk Lymphoma; 1994 Jul; 14(3-4):257-62. PubMed ID: 7950914
[TBL] [Abstract][Full Text] [Related]
10. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
Foss FM; Borkowski TA; Gilliom M; Stetler-Stevenson M; Jaffe ES; Figg WD; Tompkins A; Bastian A; Nylen P; Woodworth T
Blood; 1994 Sep; 84(6):1765-74. PubMed ID: 8080984
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models.
Bacha P; Forte S; Kassam N; Thomas J; Akiyoshi D; Waters C; Nichols J; Rosenblum M
Cancer Chemother Pharmacol; 1990; 26(6):409-14. PubMed ID: 2225311
[TBL] [Abstract][Full Text] [Related]
12. PHA induces IL-2 receptors on B-CLL cells and is a potential biological response modifier for the LIL-2-diphtheria toxin, DAB486IL-2.
Bulger K; Padua F; Duff R; Pihan G; Nichols J; Murphy J; McCaffrey R
Leuk Res; 1994 Feb; 18(2):119-22. PubMed ID: 8107488
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
LeMaistre CF; Saleh MN; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Nichols JC
Blood; 1998 Jan; 91(2):399-405. PubMed ID: 9427692
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.
Moreland LW; Sewell KL; Trentham DE; Bucy RP; Sullivan WF; Schrohenloher RE; Shmerling RH; Parker KC; Swartz WG; Woodworth TG
Arthritis Rheum; 1995 Sep; 38(9):1177-86. PubMed ID: 7575710
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L
Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein.
Grailer AP; Nichols JC; Strom TB; Sollinger HW; Burlingham WJ
Cell Immunol; 1991 Feb; 132(2):481-93. PubMed ID: 1988163
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.
LeMaistre CF; Rosenblum MG; Reuben JM; Parkinson DR; Meneghetti CM; Parker K; Shaw JP; Deisseroth AB; Woodworth T
Lancet; 1991 May; 337(8750):1124-5. PubMed ID: 1674015
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
